A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

The global primary biliary cholangitis market reached a value of nearly $979.47 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.96% since 2019.

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

Primary Biliary Cholangitis Market. Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis Market Opportunities and Strategies to 2034" report has been added to ...

Primary biliary cholangitis treatment involves medications to slow progression and relieve symptoms. Advanced cases might eventually require a liver transplant.

FDA approves Ipsen's Iqirvo for primary biliary cholangitis, ending a 10-year hiatus in new therapies for the rare cholestatic liver disease.

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.